Our Bureau

Hyderabad, Sept. 26

Aurobindo Pharma Ltd has announced that it has entered into an agreement with the US-based pharma major Gilead Sciences to manufacture and market generic versions of their anti-retroviral brand Viread (Tenofovir disoproxil fumerate) in 95 countries under the Gilead access programme.

In a press release here on Tuesday, the company said the country's classification is rated according to the Human Development index and includes high prevalence focus countries in Africa and Asia, including India. According to the company, the licensing agreements with Gilead Sciences include a technology transfer to enable expeditious production of large volumes of high quality generic version of Tenofovir DF.

(This article was published in the Business Line print edition dated September 27, 2006)
XThese are links to The Hindu Business Line suggested by Outbrain, which may or may not be relevant to the other content on this page. You can read Outbrain's privacy and cookie policy here.